A federal appeals court has overturned a decision certifying a price-fixing class action over a deal to postpone sales of a generic version of GlaxoSmithKline’s epilepsy drug Lamictal.

The U.S. Court of Appeals for the Third Circuit’s ruling provides a refresher course on a judge’s gatekeeper role in class action suits. The panel found the lower court judge granted certification without properly analyzing whether issues common to the class predominate over individual issues.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]